Dynavax Technologies Corporation Common Stock (DVAX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. See what's happening in the market right now with MarketBeat's real-time news feed. Limited Time Only. Get a FREE detailed DVAX analysis report. The company has a market cap of $964.01 million, a PE ratio of -6.39 and a beta of 1.34. Get the latest Dynavax Technologies detailed stock quotes, stock trade data, stock price info, and performance analysis, including Dynavax investment advice, charts, stats and more. FINANCIALS. Get short term trading ideas from the MarketBeat Idea Engine. LAST PRICE - 09:21am DVAX is trading DOWN -$-0.01 or -0.2% from yesterday's close of $5.12. Should I buy DVAX stock? The advice algorithm takes into account all of Dynavax Technologies' available fundamental , technical, and predictive indicators you will find on this site. Looking to buy Dynavax Technologies stock? A number of other equities research analysts also recently commented on DVAX. We aim to bring you long-term focused analysis driven by fundamental data. ©2021 Dojispace.com. Export data to Excel for your own analysis. To keep the results in a more logical format, we factor the overall opinion by 1.04 to keep the end result in multiples of 8 percentage points, with the exception of a 100% buy or sell. Learn everything you need to know about successful options trading with this three-part video course. In addition, I decide if DVAX is currently a buy, sell, or hold. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Scan for strong stocks. Dynavax, with a market capitalization of about $650 million, and a stock price up 75% over the past year, is a biotech company focusing on treating infectious and inflammatory diseases. Stock Scanner. Additionally, Dynavax CEO and director Eddie Gray informed investors he would be retiring. If you want to make a purchase, click “buy” in your broker’s user interface, enter the DVAX ticker symbol and the number of shares you want along with the price you are willing to pay. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.10. Is it Too Late to Buy Burlington Stores Stock? Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax Technologies Corporation (NASDAQ:DVAX) went up by 17.93% from its latest closing price compared to the recent 1-year high of $12.44. Here are three reasons to buy Pfizer -- and one reason to sell. The upside potential (average analyst target price relative to current price) of DVAX is higher than 86.4% of all US stocks. What To Make Of Poshmark’s First Earnings Report. Dynavax Technologies currently has an average rating of "Buy" and a consensus price target of $15.25. 2poJeff predicted that DVAX for 2020-07-17 is going $9.45 (-2.98%) 7 months ago sander7100 yo bro predicted that DVAX for 2020-07-09 is going $6.26 (-35.73%) 4 of the analysts rate the stock as a “Buy”. Find out if you should buy DVAX stock. looks like its getting ready for a move up. dvax price at support. View our full suite of financial calendars and market data tables, all for free. This story was reviewed by MarketBeat's editorial team prior to publication. Click here for a FREE analysis on DVAX. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. As a result, DVAX will explore “strategic alternatives” for its immuno-oncology (I-O) clinical assets (SD101 and DV281). According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Learn about financial terms, types of investments, trading strategies and more. Macroaxis provides Dynavax Technologies buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DVAX positions. Get daily stock ideas top-performing Wall Street analysts. Dynavax Technologies story: Buy,Sell Or Hold Dynavax Technologies Corporation At 432 Marketing Sentinel and other headlines for Dynavax Technologies Recommended Story: Understanding Options Trading, Get a free copy of the Zacks research report on Dynavax Technologies (DVAX), For more information about research offerings from Zacks Investment Research, visit Zacks.com, This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. All Rights Reserved. DVAX is trading in the range of $4.36 - $11.69 in the past 30 days. BNP Paribas Arbitrage SA now owns 25,216 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 13,320 shares in the last quarter. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. DVAX is DOWN -8% BELOW 200 day SMA. Dynavax Technologies insiders may have bought shares in the last year, but they didn't sell any. DVAX is UP 15% since the begininning of the year. Analyst recommendations provided by FactSet shows that the consensus forecast for Dynavax Technologies Corporation (DVAX) is a “Buy”. If the total is zero, then this is a "Hold". Want to see which stocks are moving? DVAX announced Thursday May 24th, 2019 AH (after hours) a strategic restructuring of the company to focus on its vaccine business. Dynavax Technologies currently has an average rating of "Buy" and a consensus price target of $15.25. Please send any questions or comments about this story to [email protected]. Finally, BNP Paribas Arbitrage SA lifted its position in Dynavax Technologies by 112.0% during the third quarter. However, it's also possible that the pharma stock will continue in its state of malaise. Dupont Capital Management Corp acquired a new position in Dynavax Technologies during the third quarter valued at approximately $202,000.
Harrisburg, Pa Real Estate, Spotify Apple Watch, North Easton Savings Bank Hours, Creamy Dinner Ideas, 9005 Alderman Dr Austin, Tx 78747, Ocean Puns Jokes, Zero-down Homes Round Rock, Tx, Villa Escondido Apartments, Hoffman-boston Elementary School, Reef Group Companies House, Tiny Tim A Christmas Carol Quotes, Joy In The Ordinary,